Artelo Biosciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Cover
- Document And Entity Information
Financial Statements
Notes to Financial Statements
Accounting Policies
- SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
Notes Tables
- EQUITY (Tables)
- DERIVATIVE LIABILITY AND FAIR VALUE MEASUREMENTS (Tables)
Notes Details

DEPOSIT

DEPOSIT	9 Months Ended
May 31, 2019
Deposits [Abstract]
DEPOSIT	NOTE 7 – DEPOSIT During the nine months ended May 31, 2019, the Company issued 61,297 shares of common stock to NEOMED for exercise of the license. The value of the common shares was $539,417 based on the stock price at agreement date.

DEPOSIT

9 Months Ended

May 31, 2019

Deposits [Abstract]

DEPOSIT

NOTE 7 – DEPOSIT

During the nine months ended May 31, 2019, the Company issued 61,297 shares of common stock to NEOMED for exercise of the license. The value of the common shares was $539,417 based on the stock price at agreement date.